IVBXF News and Press, Innovent Biologics Inc From 04/17/23

2023-04-17 09:00:14 ET Summary Sana Biotechnology has two recent pre-clinical studies that showed positive results. SANA shares were up >50% for the week, but prices are likely to slide down in the near-term. Sana Biotechnology doesn't know how to promote or position its pi...

2023-03-27 06:27:57 ET After a ~3% decline in the previous session, Incyte ( NASDAQ: INCY ) shares recovered in the pre-market trading Monday after announcing that the ministry of health in Japan approved its kinase inhibitor, Pemazyre, for bone cancer 8p11 myeloproliferative ...

Summary Jiangsu Hengrui Pharma out-licensed US rights for a novel small-molecule EZH2 inhibitor in a $706 million agreement with Connecticut's Treeline Biosciences. A CSPC Pharma subsidiary out-licensed ex-China rights for a Nectin-4 antibody drug conjugate to Boston’s Corbus Pha...

Summary Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. CS Pharmaceuticals entered a $336 million agreement for greater China rights to a PRS inhibitor, Bersipo...

Summary Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Takeda was approved to launch Exkivity (mobocertinib) in China to treat NSCLC patients with epidermal growth factor receptor (EGFR) Ex...

Summary The innovative drug maker has been approved to sell two more cancer drugs in China, but that hasn’t lifted its stock price. Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits...

Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...

Morgan Stanley says that global obesity sales in 2030 could reach $54B, driven by Eli Lilly ( NYSE: LLY ) and Novo Nordisk’s ( NVO ) ( OTCPK:NONOF ), while other large-cap pharma players closely watch their dominance amid emerging data from new biotechs. Obesi...

Shanghai Fosun Pharma will pay $158 million to acquire a 60% stake in a Singapore oncology medical center chain, Oncocare Medical Pte. OnCusp Therapeutics, a New York-Shanghai biopharma, acquired global rights (ex-China) to a pre-clinical CDH6 antibody drug conjugate from Multitude Th...

Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule. The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year ...